Serum total cholesterol and mortality in a Japanese population

Iso, Hiroyasu; Naito, Yoshihiko; Kitamura, Akihiko; Sato, Shinichi; Kiyama, Masahiko; Takayama, Yoshihiro; Iida, Minoru; Satō, Takashi; Sankai, Tomoko; Komachi, Yoshio

doi:10.1016/0895-4356(94)90110-4

Cited by 54 publications

(43 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some epidemiological studies [31][32][33] suggest that very low serum cholesterol levels are associated with an increase in total mortality. In particular, an association with cerebral hemorrhage has been reported.…”

Section: Potential Side Effects Of Very Low Ldl Cholesterolmentioning

confidence: 99%

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

Grundy¹,

Cleeman²,

Merz³

et al. 2004

Circulation

5,574

2,474

View full text Add to dashboard Cite

Abstract-The Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program issued anevidence-based set of guidelines on cholesterol management in 2001. Since the publication of ATP III, 5 major clinical trials of statin therapy with clinical end points have been published. These trials addressed issues that were not examined in previous clinical trials of cholesterol-lowering therapy. The present document reviews the results of these recent trials and assesses their implications for cholesterol management. Therapeutic lifestyle changes (TLC) remain an essential modality in clinical management. The trials confirm the benefit of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of low-density lipoprotein cholesterol (LDL-C) Ͻ100 mg/dL. They support the inclusion of patients with diabetes in the high-risk category and confirm the benefits of LDL-lowering therapy in these patients. They further confirm that older persons benefit from therapeutic lowering of LDL-C. The major recommendations for modifications to footnote the ATP III treatment algorithm are the following. In high-risk persons, the recommended LDL-C goal is Ͻ100 mg/dL, but when risk is very high, an LDL-C goal of Ͻ70 mg/dL is a therapeutic option, ie, a reasonable clinical strategy, on the basis of available clinical trial evidence. This therapeutic option extends also to patients at very high risk who have a baseline LDL-C Ͻ100 mg/dL. Moreover, when a high-risk patient has high triglycerides or low high-density lipoprotein cholesterol (HDL-C), consideration can be given to combining a fibrate or nicotinic acid with an LDL-lowering drug. For moderately high-risk persons (2ϩ risk factors and 10-year risk 10% to 20%), the recommended LDL-C goal is Ͻ130 mg/dL, but an LDL-C goal Ͻ100 mg/dL is a therapeutic option on the basis of recent trial evidence. The latter option extends also to moderately high-risk persons with a baseline LDL-C of 100 to 129 mg/dL. When LDL-lowering drug therapy is employed in high-risk or moderately high-risk persons, it is advised that intensity of therapy be sufficient to achieve at least a 30% to 40% reduction in LDL-C levels. Moreover, any person at high risk or moderately high risk who has lifestyle-related risk factors (eg, obesity, physical inactivity, elevated triglycerides, low HDL-C, or metabolic syndrome) is a candidate for TLC to modify these risk factors regardless of LDL-C level. Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy.

show abstract

Section: Potential Side Effects Of Very Low Ldl Cholesterolmentioning

confidence: 99%

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

Grundy¹,

Cleeman²,

Merz³

et al. 2004

Circulation

5,574

2,474

View full text Add to dashboard Cite

show abstract

“…In cases where insulin resistance is shown to be associated with FL it would appear logical cinogenetic agents in the animal [115][116][117]. In addition 2 epidemiologic studies [116,117] reported an excess nonto use insulin-action-enhancing drugs such as thiazolidinediones [107][108][109][110]. Trials of nonhepatotoxic insulin-en-cardiovascular mortality (including cancer mortality) in the general population with low-cholesterol levels.…”

Section: Approach To the Patient With Fl And Nashmentioning

confidence: 99%

Fatty Liver and Nonalcoholic Steatohepatitis. Where Do We Stand and Where Are We Going?

Lonardo¹

1999

Dig Dis

View full text Add to dashboard Cite

Background: Fatty liver (FL) is the most common liver disease but its clinical significance remains elusive. Nonalcoholic steatohepatitis (NASH) is increasingly recognized as a cause of liver failure, sometimes recurring following transplantation. Recent data on both conditions are critically reviewed. Methods: A Medline search of the medical literature (1990 to September 1998) and cross-references was performed. Results: FL most commonly affects middle-aged men with obesity, altered glucose metabolism, hyperlipidemia, and hypertension. The link between biology of HCV, iron metabolism and FL should be addressed. Prospective studies should also quantify the rate and the factors involved in the progression of FL to NASH. The clinical spectrum of NASH is currently broader than it was initially recognized. Diagnosis of FL and NASH may involve ultrasonography, liver biopsy, and recognition of related conditions. Treatment of these conditions must be tailored according to patient’s features. Conclusions: The clinical significance of FL is incompletely understood at present. The relationship, if any, of FL and the metabolic syndrome should be carefully investigated.

show abstract

“…The public health impact of what should be evaluated after examining other morbid conditions associated with serum cholesterol. 10,11,40 …”

Section: Study Limitationsmentioning

confidence: 99%

Low Serum Cholesterol as a Risk Factor for Hemorrhagic Stroke in Men

et al. 1999

View full text Add to dashboard Cite

Serum total cholesterol and mortality in a Japanese population

Cited by 54 publications

References 55 publications

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

Fatty Liver and Nonalcoholic Steatohepatitis. Where Do We Stand and Where Are We Going?

Low Serum Cholesterol as a Risk Factor for Hemorrhagic Stroke in Men

Contact Info

Product

Resources

About